Siblings Patents [0/32] Periodical Articles [143/144] Collection Statistics Item counts issued in 3 years:1(2.56%) Items With Fulltext:27(69.23%) Download counts of the item Download times greater than 0:27(100.00%) Download times greater than 100:27(100.00%) Total Bitstream Download Counts:15947(15.51%) Last Update: 2024-11-28 12:41 Top Upload Loading... Top Download Loading... Recent Submissions Discovery of novel AXL and MER inhi... Targeting RSPO3 reduces stem cell f... Inhibition of Rspo-Wnt pathway faci... Discovery of clinical candidate DBP... Clinical candidate DBPR112: A novel... Targeting RSPO3 reduces stem cell f... Dendritic cell-derived exosomes inc... Discovery of 2,4-diaminopyrimidines... Optimization of quinazoline-based k... Discovery of BPR1K871-a quinazoline...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 1-25 of 39. (2 Page(s) Totally) 1 2 > >> View [10|25|50] records per page

Date	Title	Relation
2023-10	Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs	Annals of Oncology. 2023 Oct;34(Suppl. 2):S214.
2019-10	Discovery of clinical candidate DBPR112, a furanopyrimidine-based epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer	Annals of Oncology. 2019 Oct;30(Suppl. 5):789.
2019-10	Inhibition of Rspo-Wnt pathway facilitates checkpoint blockade therapy by anti-RSPO3 antibody (DBPR117)	Annals of Oncology. 2019 Oct;30(Suppl. 5):191.
2018-12	Dendritic cell-derived exosomes increase the efficacy of anti-PD-L1 antibody in melanoma model	Cancer Science. 2018 Dec;109(Suppl. 2):1322.
2018-12	Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer	Cancer Science. 2018 Dec;109(SI, Suppl. 2):210.
2018-12	Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer	Cancer Science. 2018 Dec;109(Suppl. 2, SI):1257.
2018-07	Clinical candidate DBPR112: A novel epidermal growth factor receptor inhibitor as a promising treatment for non-small cell lung cancer	Cancer Research. 2018 Jul;78(13, Suppl.):Meeting Abstract 4789.
2018-01	Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer	Cancer Science. 2018 Jan;109(Suppl. 1):739.
2017-04	Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation	Abstracts of Papers of the American Chemical Society. 2017 Apr;253:Meeting Abstract 482.
2016-12	Novel cKIT kinase inhibitor, BPRCKJ001, as an advanced therapeutic candidate for GIST	Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 2P.
2015-08	Optimization of quinazoline-based kinase inhibitors: Identification of a dual FLT3/AURKA kinase inhibitor for the treatment of acute myeloid leukemia	Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 490.
2015-08	Discovery of 2,4-diaminopyrimidines bearing a unique pharmacophore as anaplastic lymphoma kinase inhibitors	Abstracts of Papers of the American Chemical Society. 2015 Aug;250:Meeting Abstract 182.
2014-11	Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent	European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93.
2014-10	Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 2530.
2014-10	Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma	Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756.
2014-03	DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study	Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI.
2014-03	Efficient virtual screening using ligand efficiency based approach	Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 55-MEDI.
2013-04-07	BPR000K, a novel Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI.
2013-04-07	3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI.
2013-04-07	Development drug candidate targeting EGFR kinase: DBPR112	Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI.
2013-04	Design and synthesis of Aurora kinase inhibitors as anticancer agents	Abstracts of Papers - American Chemical Society. 2013 Apr;245:Article number 301-MEDI.
2012-11	BPR1J271, a novel FLT3 inhibitor for treating acute myeloid leukemia	European Journal of Cancer. 2012 Nov;48(Suppl. 6):53-54.
2012-03-25	Design, synthesis, and SAR studies of duel FLT-3 and Aurora kinase inhibitors	Abstracts of Papers - American Chemical Society. 2012 Mar 25;243:Article number 48-MEDI.
2011-09-23	BPR1K653, a novel Aurora Kinase Inhibitor, exhibits potent anti-proliferative activity in P-gp170 (MDR1)-mediated VX680-resistant cancer cells in vitro and in vivo	European Journal of Cancer. 2011 Sep 23;47:S127.
2011-09	Overcoming the acquired resistance to Afatinib (BIBW2992) in HCC827, a non-small cell lung cancer cell line	European Journal of Cancer. 2011 Sep;47:S129.

Showing items 1-25 of 39. (2 Page(s) Totally) 1 2 > >> View [10|25|50] records per page